MoonLake Immunotherapeutics
MLTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MLTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MLTX
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a nanobody-based investigational therapy for inflammatory diseases, with a focus on hidradenitis suppurativa, psoriatic arthritis, and other indications.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 10 clinical trials · 5 catalysts for MoonLake Immunotherapeutics.
Similar companies
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a nanobody-based investigational therapy for inflammatory diseases, with a focus on hidradenitis suppurativa, psoriatic arthritis, and other indications.
- MoonLake has no approved products or product revenue; its sole focus is the development of sonelokimab (SLK) across multiple inflammatory indications [sec_mda · as of 2026-08-10].
- As of June 30, 2026, the company reported cash, cash equivalents, and short-term marketable securities of $537.0 million, with a projected cash runway to mid-2028 [sec_mda · as of 2026-08-10].
- The company expects to submit a first Biologics License Application (BLA) for SLK in 2026 and, subject to FDA approval, a first commercial launch in the U.S. in 2027 [sec_mda · as of 2025-05-12].
- Phase 3 VELA trials in hidradenitis suppurativa have completed enrollment and reported primary endpoint results, and a Type B FDA interaction validated the path to BLA [sec · filed 2026-04-21].
- Net losses are expected to continue for at least the next three years as the company advances clinical development and prepares for commercialization [sec_mda · as of 2025-11-05].
What works
- MoonLake has a clear regulatory path for SLK in hidradenitis suppurativa, having completed Phase 3 VELA trials and received FDA validation for the BLA pathway [sec · filed 2026-04-21].
- The company’s cash position of $537.0 million as of June 30, 2026, is projected to fund operations to mid-2028, covering completion of ongoing trials and planned Phase 3 studies [sec_mda · as of 2026-08-10].
- SLK is being developed across multiple indications (HS, PsA, axSpA, PPP, adolescent HS), diversifying potential market opportunities [sec_mda · as of 2026-05-11].
What to weigh
- MoonLake has no approved products or revenue from product sales, and its ability to generate revenue depends entirely on the successful development and commercialization of SLK [sec_mda · as of 2026-08-10].
- The company expects to continue incurring significant operating losses for at least the next three years, with net losses fluctuating based on clinical trial timing and regulatory activities [sec_mda · as of 2025-11-05].
- As a single-asset company, MoonLake is highly dependent on the clinical and regulatory success of SLK; any setbacks could materially impact its business [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
MoonLake has no approved products or product revenue.
“We have no products approved for commercial sale, have not generated any revenue from product sales, and cannot guarantee when or if we will generate any revenue from product sales.”
SEC MD&A · August 10, 2026
Cash runway is projected to mid-2028.
“Based on our current operating plan, we believe that we have sufficient capital to fund our operations and capital expenditures to mid-2028.”
SEC MD&A · August 10, 2026
Phase 3 VELA trials in HS completed with primary endpoint results and FDA validation.
“Completed enrollment and reported primary endpoint results of the Phase 3 VELA trials in hidradenitis suppurativa, and successfully conducted a subsequent Type B interaction with the FDA to validate the path to BLA”
SEC filings · April 21, 2026
First BLA submission expected in 2026, commercial launch in 2027.
“We expect to submit a first Biologics License Application ("BLA") for SLK in 2026 and, subject to FDA approval, a first commercial launch in the U.S. in 2027.”
SEC MD&A · May 12, 2025
Catalyst timeline
- 2026-09-28 · Phase3_Topline — Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki — Topline results from a pharmacokinetics and safety study of sonelokimab will provide data on dosing and safety in the target population.
- 2027-01-15 · Phase3_Topline · risankizumab — Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study Wi — Topline results from a Phase 3 trial comparing sonelokimab to risankizumab and placebo will assess efficacy and safety in a key inflammatory indication.
- 2027-02-04 · Phase3_Topline — Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to — Topline results from another Phase 3 trial will further evaluate sonelokimab's efficacy and safety versus placebo.
- 2028-02-04 · Phase3_Topline — Phase 3 Topline: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in — Long-term safety and efficacy data from an open-label extension study will inform the durability of sonelokimab's effects.
- 2028-06-13 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, a — Additional long-term safety and tolerability data from an open-label extension study will support the product's risk-benefit profile.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — MoonLake has no commercial products and no product revenue; future revenue depends entirely on SLK's development and approval [sec_mda · as of 2026-08-10].
- Single-asset dependency — The company's pipeline is solely focused on sonelokimab; any clinical or regulatory failure would severely impact the business [sec_mda · as of 2026-08-10].
- Continued operating losses — Net losses are expected for at least the next three years, with fluctuations based on trial timing and regulatory milestones [sec_mda · as of 2025-11-05].
- Regulatory and commercial uncertainty — BLA submission and FDA approval are not guaranteed; commercial launch timelines depend on successful regulatory outcomes [sec_mda · as of 2025-05-12].
What to watch
- BLA submission for SLK in hidradenitis suppurativa, expected in 2026 [sec_mda · as of 2025-05-12].
- Phase 3 topline data readouts for SLK in psoriatic arthritis (IZAR-1/IZAR-2) and other indications [sec · filed 2026-04-21].
- FDA decision on the BLA and potential first commercial launch in the U.S. in 2027 [sec_mda · as of 2025-05-12].
- Cash burn rate and any updates to the projected cash runway to mid-2028 [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 13, 2026 · How we verify sources →
Run MoonLake Immunotherapeutics through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MoonLake Immunotherapeutics facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
29.4 months
D/E 0.34 · 0% dilution
Lead: Phase 2
1 candidate
5 upcoming, next in ~29d
0 buys · 23 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
145
Total value held
$1.13B
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 16,001,284 | $298.3M |
| janus henderson group plc | 6,903,256 | $128.6M |
| deep track capital, lp | 6,408,863 | $119.5M |
| d. e. shaw & co., inc. | 2,390,661 | $44.6M |
| citadel advisors llc | 2,081,728 | $38.8M |
| vivo capital, llc | 2,000,000 | $37.3M |
| mpm bioimpact llc | 1,811,082 | $33.8M |
| weiss asset management lp | 1,708,328 | $31.8M |
| susquehanna international group, llp | 1,208,624 | $22.5M |
| goldman sachs group inc | 1,130,233 | $21.1M |
Showing top 10 of 145 institutional holders of MoonLake Immunotherapeutics. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 21.2%
- Days to cover
- 8.4
- Shares short
- 7,757,169
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MLTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a nanobody-based investigational therapy for inflammatory diseases, with a focus on hidradenitis suppurativa, psoriatic arthritis, and other indications.
What is MoonLake Immunotherapeutics's lead drug candidate?
MoonLake Immunotherapeutics's most advanced tracked candidate is SLK (Phase 2) for Axial spondyloarthritis (axSpA).
What is MoonLake Immunotherapeutics's next catalyst?
MoonLake Immunotherapeutics's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki" — expected September 28, 2026.
Who is the CEO of MoonLake Immunotherapeutics?
Dr. Jorge Santos da Silva Ph.D. is the chief executive officer of MoonLake Immunotherapeutics (MLTX).
Where is MoonLake Immunotherapeutics headquartered?
MoonLake Immunotherapeutics (MLTX) is headquartered in Zug, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.